TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

05 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

03 سبتمبر 2024 09:50:10 بحسب NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

21 أغسطس 2024 14:44:15 بحسب NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

19 أغسطس 2024 09:49:32 بحسب NetDania Notify

TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

06 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

05 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

17 يوليو 2024 09:58:20 بحسب NetDania Notify

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

07 يونيو 2024 07:50:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

03 يونيو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

31 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

28 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

01 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

30 أبريل 2024 16:55:29 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

18 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

18 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

15 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

08 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

01 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

28 فبراير 2024 07:00:01 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

27 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire